Kellehermendoza3835
Non-alcoholic fatty liver disease (NAFLD) as the most common chronic liver disease is closely linked to type 2 diabetes mellitus (T2DM). Omega-3 supplementation has been proposed as a strategy to manage T2DM and NAFLD. The present study aimed to investigate the effect of omega-3 supplementation on fatty liver index, lipid accumulation product and visceral adiposity index in diabetic patients with NAFLD.
In this 12-week double-blind, randomized controlled clinical trial, sixty diabetic patients with NAFLD were randomly assigned into the omega-3 and placebo groups for 12 weeks. The omega-3 group received 2000mg/d omega-3 as capsule.
Fifty-six participants completed the study. No significant difference was found between the two groups in the terms of fatty liver index, lipid accumulation product and visceral adiposity index at the baseline. Omega-3 supplementation compared with the placebo led to a significant improvement in fatty liver index (-3.6±12.1 vs. 0.9±8.9; P=0.04), lipid accumulation product (-14.2±27.9 vs. 8.0±26.3; P=0.002) and visceral adiposity index (-0.5±0.9 vs. 0.0±0.8; P=0.01).
Omega-3 supplementation for 12 weeks improves fatty liver index, lipid accumulation product and visceral adiposity index. The study protocol was registered under Iranian Registry of Clinical Trials identifier number IRCT2016102530489N1.
Omega-3 supplementation for 12 weeks improves fatty liver index, lipid accumulation product and visceral adiposity index. The study protocol was registered under Iranian Registry of Clinical Trials identifier number IRCT2016102530489N1.
Omega-3 is a supplement that promotes several health benefits. The evidence on omega-3 in weight loss or body fat mass is inconclusive. This study aimed to review the literature on studies that evaluated the effect of omega-3 supplementation and changes in weight and/or body fat mass in humans.
A systematic review, following the recommendations of PRISMA, in the databases Pubmed, Lilacs, and Scielo. Only experimental studies in humans that evaluated the effects of supplementation with omega-3 on weight loss and/or body fat mass were included.
In total, 20 studies were selected, of which 11 found no effect, and the other nine find some benefits. Two studies found a reduction in individuals' body fat, and a third found these results in women and a fourth only in men. In children and adolescents, one study found a difference in weight loss between groups. Four studies reported decreased body weight in women, and in men, only one found this result.
To date, there is no consistency in the literature that omega-3 has benefits in weight loss or body fat mass in humans. Due to the studies' heterogeneity and inconsistency in the results, further studies on the subject are necessary.
To date, there is no consistency in the literature that omega-3 has benefits in weight loss or body fat mass in humans. Due to the studies' heterogeneity and inconsistency in the results, further studies on the subject are necessary.
We evaluated the efficacy of the intervention consisting of amino acid/protein supplementation on muscle mass, muscle strength and physical function in patients on hemodialysis.
This systematic review and meta-analysis identified potential studies through a systematic search of 4 electronic databases and references from eligible studies from database inception to August 2020. We included only randomized controlled trials reporting the efficacy of amino acid/protein supplementation on muscle mass, muscle strength and physical function in patients on hemodialysis.
Of 6529 unique citation records, 4 studies including 243 participants were selected for inclusion in the meta-analysis. Although there were no significant differences in muscle mass and muscle strength between the intervention and control groups, amino acid/protein supplementation was shown to significantly improve physical function (shuttle walk, MD 32.7, 95% CI 21.7 to 43.7, P<0.001; gait speed, MD 0.07, 95% CI 0.01 to 0.13, P=0.02; timed up and go, MD -0.42, 95% CI -0.68 to-0.15, P=0.002) in patients on hemodialysis.
We confirmed the positive effect of amino acid/protein supplementation on physical function in people undergoing hemodialysis. However, there is still insufficient evidence, and more rigorously designed randomized controlled trials with high quality are needed.
We confirmed the positive effect of amino acid/protein supplementation on physical function in people undergoing hemodialysis. However, there is still insufficient evidence, and more rigorously designed randomized controlled trials with high quality are needed.
Results from narrative reviews showed potential from omega-3 supplementation on lean body mass. In older adults, a previous meta-analysis showed significant results from omega-3 on lean body mass. This review aimed to investigate randomized clinical trials that evaluated the effects of omega-3 supplementation, compared to placebo, on lean body mass in humans.
A systematic review and meta-analysis were conducted in Pubmed, LILACS, SciELO, Web of Science, Scopus, Embase, SPORTDiscus, and Cochrane Library. The authors assessed the risk of bias using the Cochrane tool. Randomized clinical trials that evaluated the effects of omega-3 supplementation compared to placebo on lean body mass were included.
In total, 11 studies were included, from which two found significant effects on lean body mass. In the meta-analysis, none of the results were significant.
Omega-3 supplementation had no significant effect on lean body mass compared to placebo.
Omega-3 supplementation had no significant effect on lean body mass compared to placebo.
The prevention and treatment of non-alcoholic fatty liver disease (NAFLD) has become one of the most urgent problems to be solved. To date, only a lifestyle modification related to diet and physical activity is considered for these patients. Polyphenols are a group of plant natural products that when regularly consumed has been related to a reduction in the risk of several metabolic disorders associated with NAFLD. In this study, we aimed to present an overview of the relationship between polyphenols and NAFLD with current approaches.
We performed a comprehensive literature search for articles on polyphenols and NAFLD published in English between January 2018 to August 2020. Keywords included in this review "Phenolic" OR "Polyphenol" AND "Non-Alcoholic Fatty Liver Disease". The editorials, communications and conference abstracts were excluded.
Different polyphenols decreased the pro-inflammatory cytokines in both serum and liver that contribute to a decrease in fatty liver dysfunction. click here Additionally, polyphenols may improve the regulation of adipokines and prevent hepatic steatosis. According to human clinical studies, polyphenols are promising for NAFLD patients and associated diseases that lead to NAFLD.
Preclinical and clinical studies suggest that various polyphenols could prevent steatosis and its progression to non-alcoholic steatohepatitis, as well as ameliorate NAFLD. However, more clinical studies are needed to confirm this hypothesis.
Preclinical and clinical studies suggest that various polyphenols could prevent steatosis and its progression to non-alcoholic steatohepatitis, as well as ameliorate NAFLD. However, more clinical studies are needed to confirm this hypothesis.One of the major effects of the COVID-19 pandemic within nuclear medicine was to halt performance of lung ventilation studies, due to concern regarding spread of contaminated secretions into the ambient air. A number of variant protocols for performing lung scintigraphy emerged in the medical literature which minimized or eliminated the ventilation component, due to the persistent need to provide this critical diagnostic service without compromising the safety of staff and patients. We have summarized and reviewed these protocols, many of which are based on concepts developed earlier in the history of lung scintigraphy. It is possible that some of these interim remedies may gain traction and earn a more permanent place in the ongoing practice of nuclear medicine.8-oxoguanine DNA glycosylase (OGG), which plays a crucial role in base excision repair (BER), is an important biomarker. The existing highly sensitive fluorescent methods always need complicated amplification design. The method with high sensitivity and simple design at the same time is urgently needed. Here, we developed a highly sensitive detection method for OGG detection with lambda exonuclease and the background signal suppression probe. Through probe structure design, the steric hindrance and competitive binding effects successfully suppressed the background signal. We achieved sensitive detection of OGG with a simple design, and the limit of detection was 5.0 × 10-4 U mL-1. Moreover, the method was highly selective and successfully applied to OGG detection in biological samples, which shows the potential clinical application value.Undoubtedly, light-emitting diodes (LEDs) and photodiodes (PDs) are indispensable optoelectronic devices in modern analytical chemistry. LEDs can serve as either light emitters or detectors, thus being an alternative to the most popular detection systems consisted of PD. In this contribution, a comparison between LED-LED and LED-PD detectors, operating in turbidimetric and nephelometric modes, has been carried out for immunoprecipitation detection of transferrin and ferritin. The greatest emphasis was placed on the study of detectors responses under different measurement conditions including current powering an emitter, amplification gain in the case of PD as detector or the construction of detection cells designed for the Multicommutated Flow Analysis (MCFA). The assumption was to obtain the fully-mechanized system with simple but efficient detection system to enable the determination of iron-binding proteins occurring at different concentration ranges in human body. As a result, the optimized arrangements of LED-LED and LED-PD setups were characterized by similar analytical characteristics, enabling the determination of transferrin with the detection limit (LOD) of 0.2 mg/L and RSDs of 2.8-4.8% for LED-LED, and LOD of 0.1 mg/L and RSDs of 0.9-3.6% for LED-PD. In the case of ferritin detection, only the response of the LED-PD detector was statistically distinguishable in the range of 130-198 μg/L of protein with recorded analytical signal change of 20 mV value. The addition of polymer for signal enhancement provided the increase of response range to 107-253 μg/L, enabling the developed system for detection of pathological serum ferritin levels.A new disposable amperometric biosensor for sarcosine (Sar, a biomarker for prostate cancer) was designed based on screen-printed carbon electrodes, Prussian blue, polymer dispersed reduced graphene oxide (P-rGO) nanosheets, and sarcosine oxidase (SOx). Poly(sodium 4-styrenesulfonate-r-LAHEMA) denoted as PSSL was newly synthesized as dispersant for rGO. The P-rGO was utilized for SOx immobilization, the sulfonate and disulfide functionalities in PSSL enable physical adsorption of SOx and its bioactivity and stability properties were improved. The biosensor was optimized by various enzyme concentration, applied potential, and operating pH. Under the optimized conditions, the biosensor exhibited maximum current responses within 5 s at an applied potential of -0.1 V vs. integrated Ag/AgCl reference electrode. The biosensor had a dynamic linear range of 10-400 μM, with a sensitivity of 9.04 μA mM-1 cm-2 and a low detection limit of 0.66 μM (S/N = 3). Additionally, the biosensor possesses strong anti-interference capability, high reproducibility, and storage stability over 3 weeks.
